Biologic Therapy for Children with IBD
Part of Digestive system, Immune system & allergy clinical trials.
This trial tests a biologic therapy for children with inflammatory bowel disease (IBD) who have severe disease or a flare-up and need to start or switch treatments. It aims to see how well the medicine works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be diagnosed with inflammatory bowel disease (IBD) using standard tests.
- They must have a severe case or a flare-up and be planning to start or change to a biologic medicine.
- They cannot already be on a biologic and doing well.
- They cannot have a known immune system deficiency.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study monitors levels of certain medications (infliximab, adalimumab, vedolizumab, ustekinumab) in children with inflammatory bowel disease to see if adjusting the dose helps them feel better. It aims to improve treatment outcomes.
This study looks at how well different biologic medications work for people with moderate to severe ulcerative colitis or Crohn's disease after one year of treatment. The goal is to see which treatment helps the gut heal best.
This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.
This trial is looking at children and teenagers with Crohn's disease or ulcerative colitis who are starting a biologic medicine called infliximab. It aims to learn more about how this treatment works in young patients.
This trial compares two treatment approaches for children newly diagnosed with ulcerative colitis: starting with stronger medicines right away versus beginning simpler and stepping up if needed. It may help your child learn which strategy controls symptoms better with fewer flare-ups.
This study looks at why some people with inflammatory bowel disease (Crohn's or ulcerative colitis) do not respond to certain biologic treatments. Researchers will use advanced testing (multi-omics) to better understand treatment response. If you are starting or have just started treatment with infliximab, adalimumab, vedolizumab, or ustekinumab, you may be able to join.
Hear when a new Effect of Drug trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.